Expression Levels of LINC01296 and LINC00152 in Breast
Cancer Tissue: Association with the Use of Oral Contraceptives

TABEİ, Seyed Mohammadbagher; KHANI, Pouria; FARAHANİ, Mostafa Davoodabadi; MAZLOOMREZAI, Mohsen; Neamatzadeh, Hossein; BARAHMAN, Maedeh; ILBEIGI, Shahrzad; DASTGHELB, Seyed Alireza; MANSOORİ, Yaser

doi:10.14744/ejmo.2022.33174

Expression Levels of LINC01296 and LINC00152 in Breast Cancer Tissue: Association with the Use of Oral Contraceptives

Mostafa Davoodabadi FARAHANİ, (Department of Medical Genetics, Shiraz University of Medical Sciences, Faculty of Medicine, Shiraz, Iran)

Yaser MANSOORİ, (Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran)

Shahrzad ILBEIGI, (Department of Medical Genetics, Shiraz University of Medical Sciences, Faculty of Medicine, Shiraz, Iran)

Maedeh BARAHMAN, (Firoozgar Clinical Research Development Center (FCRDC), Firoozgar Hospital, Iran University of Medical Sciences, Tehran, Iran)

Mohsen MAZLOOMREZAI, (Cellular and Molecular Students Research Group, Shiraz University of Medical Sciences, Faculty of Medicine, Shiraz, Iran)

Pouria KHANI, (Department of Medical Genetics and Molecular Biology, Iran University of Medical Sciences, Faculty of Medicine, Tehran, Iran)

Seyed Mohammadbagher TABEİ, (Department of Medical Genetics, Shiraz University of Medical Sciences, Faculty of Medicine, Shiraz, Iran)

Seyed Alireza DASTGHELB, (Department of Medical Genetics, Shiraz University of Medical Sciences, Faculty of Medicine, Shiraz, Iran)

Hossein NEAMATZADEH (Department of Medical Genetics, Shahid Sadoughi University of Medical Sciences, Yazd, Iran)

Eurasian Journal of Medicine and Oncology

2 0

Yıl: 2022 Cilt: 6 Sayı: 1 Sayfa Aralığı: 83 - 88 Metin Dili: İngilizce DOI: 10.14744/ejmo.2022.33174 İndeks Tarihi: 18-06-2022

Expression Levels of LINC01296 and LINC00152 in Breast Cancer Tissue: Association with the Use of Oral Contraceptives

Öz:

Objectives: Breast cancer is among the most commonly diagnosed cancers and one of the main causes of cancerrelated deaths in females. Long noncoding RNAs (lncRNA) are vital regulators of both oncogenesis and tumor suppression involved in crucial cancer pathways. Recent studies have demonstrated that LINC01296 and LINC00152 were aberrantly upregulated in different tumor types. In this study, we aimed to assess the expression levels of LINC01296 and LINC00152 in breast cancer and its adjacent tissues. Methods: Sample tissues were collected from 49 women with breast cancer referred to Shahid Faghihi Hospital in Shiraz for surgery from 2017 to 2018. Total RNA was extracted from fresh tumor and normal breast cancer tissues and expression of lncRNAs was assessed using real-time polymerase chain reaction. Results: A significant upregulation of LINC01296 and LINC00152 in breast cancer tissues compared with the adjacent normal tissues was observed (p<0.01). The Mann–Whitney analysis showed a significant relationship between the upregulation of LINC01296 and the use of oral contraceptives in luminal B breast cancer subjects (p=0.028). No significant relationship was found between the expression of LINC01296 and quantitative variables. Conclusion: This study showed an upregulation of LINC01296 and LINC00152 in breast cancer tissues compared with the adjacent normal tissues.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Karimi-Zarchi M, Dehghani-Firoozabadi R, Tabatabaie A, Dehghani- Firoozabadi Z, Teimoori S, Chiti Z, et al. A comparison of the effect of levonorgestrel IUD with oral medroxyprogesterone acetate on abnormal uterine bleeding with simple endometrial hyperplasia and fertility preservation. Clin Exp Obstet Gynecol 2013;40:421–4.
2. Azadi-Yazdi M, Karimi-Zarchi M, Salehi-Abargouei A, Fallahzadeh H, Nadjarzadeh A. Effects of dietary approach to stop hypertension diet on androgens, antioxidant status and body composition in overweight and obese women with polycystic ovary syndrome: a randomised controlled trial. J Hum Nutr Diet 2017;30:275–83.
3. Moghimi M, Sobhan MR, Jarahzadeh MH, Morovati-Sharifabad M, Aghili K, Ahrar H, et al. Association of GSTM1, GSTT1, GSTM3, and GSTP1 genes polymorphisms with susceptibility to osteosarcoma: a case- control study and meta-analysis. Asian Pac J Cancer Prev 2019;20:675–82.
4. Ahmadi SAY, Sayad S, Shahsavar F, Nekouian R, Panahi M, Sayad S, et al. Expression of angiogenesis-related genes in a group of Iranian cases of breast cancer. Curr Pharmacogenomics Person Med 2021;17:197–205.
5. Farbod M, Karimi-Zarchi M, Heiranizadeh N, Seifi-Shalamzari N, Akbarian-Bafghi MJ, Jarahzadeh MH, et al. Association of TNF-α -308G>A polymorphism with susceptibility to cervical cancer and breast cancer – a systematic review and meta- analysis. Klinicka Onkologie 2019; 32:170–80.
6. Dastgheib SA, Asadian F, Farbod M, Karimi-Zarchi M, Meibodi B, Akbarian E, et al. Association of ACE I/D, -240A > T and AT1R A1166C polymorphisms with susceptibility to breast cancer: a systematic review and meta-analysis based on 35 case-control studies. Nucleosides Nucleotides Nucleic Acids 2021;40:117–35.
7. Moghimi M, Kargar S, Jafari MA, Ahrar H, Jarahzadeh MH, Neamatzadeh H, et al. Angiotensin converting enzyme insertion/ deletion polymorphism is associated with breast cancer risk: a meta-analysis. Asian Pac J Cancer Prev 2018;19:3225–31.
8. Forat-Yazdi M, Neamatzadeh H, Sheikhha MH, Zare-Shehneh M, Fattahi M. BRCA1 and BRCA2 common mutations in Iranian breast cancer patients: a meta analysis. Asian Pac J Cancer Prev 2015;16:1219–24.
9. Sheikhpour E, Noorbakhsh P, Foroughi E, Farahnak S, Nasiri R, Neamatzadeh H. A survey on the role of interleukin-10 in breast cancer: a narrative. Rep Biochem Mol Biol 2018;7:30–7.
10. Akbari MT, Naderi A, Saremi L, Sayad A, Irani S, Ahani A. Methionine synthase A2756G variation is associated with the risk of retinoblastoma in children. Cancer Epidemiol 2015;39:1023–5.
11. Yazdi MF, Rafieian S, Gholi-Nataj M, Sheikhha MH, Nazari T, Neamatzadeh H. CYP2D6 genotype and risk of recurrence in tamoxifen treated breast cancer patients. Asian Pac J Cancer Prev 2015;16:6783–7.
12. Moghimi M, Ahrar H, Karimi-Zarchi M, Aghili K, Salari M, Zare- Shehneh M, et al. Association of IL-10 rs1800871 and rs1800872 Polymorphisms with breast cancer risk: a systematic review and meta-analysis. Asian Pac J Cancer Prev 2018;19:3353–9.
13. Jafari-Nedooshan J, Moghimi M, Zare M, Heiranizadeh N, Morovati- Sharifabad M, Akbarian-Bafghi MJ, et al. Association of promoter region polymorphisms of IL-10 gene with susceptibility to lung cancer: systematic review and meta-analysis. Asian Pac J Cancer Prev 2019;20:1951–7.
14. Baghestani AR, Shahmirzalou P, Sayad S, Akbari ME, Zayeri F. Comparison cure rate models by DIC criteria in Breast Cancer data. Asian Pac J Cancer Prev 2018;19:1601–6.
15. Feng Y, Spezia M, Huang S, Yuan C, Zeng Z, Zhang L, et al. Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes Dis 2018;5:77–106.
16. Scola L, Vaglica M, Crivello A, Palmeri L, FORTE GI, MACALUSO MC, et al. Cytokine gene polymorphisms and breast cancer susceptibility. Ann NY Acad Sci 2006;1089:104–9.
17. Tomar D, Yadav AS, Kumar D, Bhadauriya G, Kundu GC. Non-coding RNAs as potential therapeutic targets in breast cancer. Biochim Biophys Acta Gene Regul Mech 2020;1863:194378.
18. Crudele F, Bianchi N, Reali E, Galasso M, Agnoletto C, Volinia S. The network of non-coding RNAs and their molecular targets in breast cancer. Mol Cancer 2020;19:61.
19. Catalanotto C, Cogoni C, Zardo G. MicroRNA in control of gene expression: an overview of nuclear functions. Int J Mol Sci 2016;17:1712.
20. Sayad S, Ahmadi SAY, Moradi M, Nekouian R, Anbari K, Shahsavar F. A meta-analysis on diagnostic accuracy of serum HLA-G level in breast cancer. Expert Rev Precis Med Drug Dev 2020;5:109–14.
21. Rinn JL, Chang HY. Genome regulation by long noncoding RNAs. Annu Rev Biochem 2012;81:145–66.
22. Sanchez Calle A, Kawamura Y, Yamamoto Y, Takeshita F, Ochiya T. Emerging roles of long non-coding RNA in cancer. Cancer Sci 2018;109:2093-100.
23. Zhang G, He X, Ren C, Lin J, Wang Q. Long noncoding RNA PCA3 regulates prostate cancer through sponging miR-218- 5p and modulating high mobility group box 1. J Cell Physiol 2019;234:13097–109.
24. Sun Y, Ma L. New insights into long non-coding RNA MALAT1 in cancer and metastasis. Cancers (Basel) 2019;11:216. 25. Chen X, Qu J. Long non-coding RNA MEG3 suppresses survival, migration, and invasion of cervical cancer. Onco Targets Ther 2018;11:4999–5007.
26. Li J, Yang C, Li Y, Chen A, Li L, You Z. LncRNA GAS5 suppresses ovarian cancer by inducing inflammasome formation. Bioscience Reports 2018;38:BSR20171150.
27. Wu J, Shuang Z, Zhao J, Tang H, Liu P, Zhang L, et al. Linc00152 promotes tumorigenesis by regulating DNMTs in triple-negative breast cancer. Biomed Pharmacother 2018;97:1275–81.
28. Jiang M, Xiao Y, Liu D, Luo N, Gao Q, Guan Y. Overexpression of long noncoding RNA LINC01296 indicates an unfavorable prognosis and promotes tumorigenesis in breast cancer. Gene 2018;675:217–24.
29. Feng W, Zhai C, Shi W, Zhang Q, Yan X, Wang J, et al. Clinicopathological and prognostic value of LINC01296 in cancers: a meta-analysis. Artif Cells Nanomed Biotechnol 2019;47:3315– 21.
30. Hunter DJ, Colditz GA, Hankinson SE, Malspeis S, Spiegelman D, Chen W, et al. Oral contraceptive use and breast cancer: a prospective study of young women. Cancer Epidemiol Biomarkers Prev 2010;19:2496–502.
31. Mansoori Y, Tabei MB, Askari A, Izadi P, Daraei A, Naghizadeh MM, et al. A link between expression level of long-non-coding RNA ZFAS1 in breast tissue of healthy women and obesity. Int J Biol Markers 2018;33:500–6.
32. Mansoori Y, Tabei MB, Askari A, Izadi P, Daraei A, Bastami M, et al. Expression levels of breast cancer-related GAS5 and LSINCT5 lncRNAs in cancer-free breast tissue: Molecular associations with age at menarche and obesity. Breast J 2018;24:876–82.

APA	FARAHANİ M, MANSOORİ Y, ILBEIGI S, BARAHMAN M, MAZLOOMREZAI M, KHANI P, TABEİ S, DASTGHELB S, Neamatzadeh H (2022). Expression Levels of LINC01296 and LINC00152 in Breast Cancer Tissue: Association with the Use of Oral Contraceptives. , 83 - 88. 10.14744/ejmo.2022.33174
Chicago	FARAHANİ Mostafa Davoodabadi,MANSOORİ Yaser,ILBEIGI Shahrzad,BARAHMAN Maedeh,MAZLOOMREZAI Mohsen,KHANI Pouria,TABEİ Seyed Mohammadbagher,DASTGHELB Seyed Alireza,Neamatzadeh Hossein Expression Levels of LINC01296 and LINC00152 in Breast Cancer Tissue: Association with the Use of Oral Contraceptives. (2022): 83 - 88. 10.14744/ejmo.2022.33174
MLA	FARAHANİ Mostafa Davoodabadi,MANSOORİ Yaser,ILBEIGI Shahrzad,BARAHMAN Maedeh,MAZLOOMREZAI Mohsen,KHANI Pouria,TABEİ Seyed Mohammadbagher,DASTGHELB Seyed Alireza,Neamatzadeh Hossein Expression Levels of LINC01296 and LINC00152 in Breast Cancer Tissue: Association with the Use of Oral Contraceptives. , 2022, ss.83 - 88. 10.14744/ejmo.2022.33174
AMA	FARAHANİ M,MANSOORİ Y,ILBEIGI S,BARAHMAN M,MAZLOOMREZAI M,KHANI P,TABEİ S,DASTGHELB S,Neamatzadeh H Expression Levels of LINC01296 and LINC00152 in Breast Cancer Tissue: Association with the Use of Oral Contraceptives. . 2022; 83 - 88. 10.14744/ejmo.2022.33174
Vancouver	FARAHANİ M,MANSOORİ Y,ILBEIGI S,BARAHMAN M,MAZLOOMREZAI M,KHANI P,TABEİ S,DASTGHELB S,Neamatzadeh H Expression Levels of LINC01296 and LINC00152 in Breast Cancer Tissue: Association with the Use of Oral Contraceptives. . 2022; 83 - 88. 10.14744/ejmo.2022.33174
IEEE	FARAHANİ M,MANSOORİ Y,ILBEIGI S,BARAHMAN M,MAZLOOMREZAI M,KHANI P,TABEİ S,DASTGHELB S,Neamatzadeh H "Expression Levels of LINC01296 and LINC00152 in Breast Cancer Tissue: Association with the Use of Oral Contraceptives." , ss.83 - 88, 2022. 10.14744/ejmo.2022.33174
ISNAD	FARAHANİ, Mostafa Davoodabadi vd. "Expression Levels of LINC01296 and LINC00152 in Breast Cancer Tissue: Association with the Use of Oral Contraceptives". (2022), 83-88. https://doi.org/10.14744/ejmo.2022.33174

APA	FARAHANİ M, MANSOORİ Y, ILBEIGI S, BARAHMAN M, MAZLOOMREZAI M, KHANI P, TABEİ S, DASTGHELB S, Neamatzadeh H (2022). Expression Levels of LINC01296 and LINC00152 in Breast Cancer Tissue: Association with the Use of Oral Contraceptives. Eurasian Journal of Medicine and Oncology, 6(1), 83 - 88. 10.14744/ejmo.2022.33174
Chicago	FARAHANİ Mostafa Davoodabadi,MANSOORİ Yaser,ILBEIGI Shahrzad,BARAHMAN Maedeh,MAZLOOMREZAI Mohsen,KHANI Pouria,TABEİ Seyed Mohammadbagher,DASTGHELB Seyed Alireza,Neamatzadeh Hossein Expression Levels of LINC01296 and LINC00152 in Breast Cancer Tissue: Association with the Use of Oral Contraceptives. Eurasian Journal of Medicine and Oncology 6, no.1 (2022): 83 - 88. 10.14744/ejmo.2022.33174
MLA	FARAHANİ Mostafa Davoodabadi,MANSOORİ Yaser,ILBEIGI Shahrzad,BARAHMAN Maedeh,MAZLOOMREZAI Mohsen,KHANI Pouria,TABEİ Seyed Mohammadbagher,DASTGHELB Seyed Alireza,Neamatzadeh Hossein Expression Levels of LINC01296 and LINC00152 in Breast Cancer Tissue: Association with the Use of Oral Contraceptives. Eurasian Journal of Medicine and Oncology, vol.6, no.1, 2022, ss.83 - 88. 10.14744/ejmo.2022.33174
AMA	FARAHANİ M,MANSOORİ Y,ILBEIGI S,BARAHMAN M,MAZLOOMREZAI M,KHANI P,TABEİ S,DASTGHELB S,Neamatzadeh H Expression Levels of LINC01296 and LINC00152 in Breast Cancer Tissue: Association with the Use of Oral Contraceptives. Eurasian Journal of Medicine and Oncology. 2022; 6(1): 83 - 88. 10.14744/ejmo.2022.33174
Vancouver	FARAHANİ M,MANSOORİ Y,ILBEIGI S,BARAHMAN M,MAZLOOMREZAI M,KHANI P,TABEİ S,DASTGHELB S,Neamatzadeh H Expression Levels of LINC01296 and LINC00152 in Breast Cancer Tissue: Association with the Use of Oral Contraceptives. Eurasian Journal of Medicine and Oncology. 2022; 6(1): 83 - 88. 10.14744/ejmo.2022.33174
IEEE	FARAHANİ M,MANSOORİ Y,ILBEIGI S,BARAHMAN M,MAZLOOMREZAI M,KHANI P,TABEİ S,DASTGHELB S,Neamatzadeh H "Expression Levels of LINC01296 and LINC00152 in Breast Cancer Tissue: Association with the Use of Oral Contraceptives." Eurasian Journal of Medicine and Oncology, 6, ss.83 - 88, 2022. 10.14744/ejmo.2022.33174
ISNAD	FARAHANİ, Mostafa Davoodabadi vd. "Expression Levels of LINC01296 and LINC00152 in Breast Cancer Tissue: Association with the Use of Oral Contraceptives". Eurasian Journal of Medicine and Oncology 6/1 (2022), 83-88. https://doi.org/10.14744/ejmo.2022.33174